To date, nearly one-quarter of colorectal cancer (CRC) patients develop liver metastases (CRCLM), and its aggressiveness can be correlated to defined histopathological growth patterns (HGP). From the three main HGPs within CRCLM, the replacement HGP emerges as particularly aggressive, characterized by heightened tumor cell motility and vessel co-option. Here, we investigated the correlation between the expression of calcium- and integrin-binding protein 1 (CIB1), a ubiquitously expressed gene involved in various cellular processes including migration and adhesion, and disease-free (DFS) and overall survival (OS) in primary CRC patients. Additionally, we explored the correlation between CIB1 expression and different HGPs of CRCLM. Proteomic analysis was used to evaluate CIB1 expression in a cohort of 697 primary CRC patients. Additionally, single-cell and spatial RNA-sequencing datasets, along with publicly available bulk sequencing data were used to evaluate CIB1 expression in CRCLM. In silico data were further validated by formalin-fixed paraffin-embedded immunohistochemical stainings. We observed that high CIB1 expression is independently associated with worse DFS and OS, regardless of Union Internationale Contre le Cancer stage, gender, or age. Furthermore, the aggressive replacement CRCLM HGP is significantly associated with high CIB1 expression. Our findings show a correlation between CIB1 levels and the clinical aggressiveness of CRC. Moreover, CIB1 may be a novel marker to stratify HGP CRCLM.
High CIB1 expression in colorectal cancer liver metastases correlates with worse survival and the replacement histopathological growth pattern.
结直肠癌肝转移中 CIB1 高表达与较差的生存率和替代性组织病理学生长模式相关
阅读:4
作者:Fan Shuang, Fleischer Johannes Robert, Dokshokova Lolita, Böhme Lena Sophie, Haas Gwendolyn, Schmitt Alexandra Maria, Gätje Fabio Bennet, Rosen Linde-Allegra Emmalie, Bohnenberger Hanibal, Ghadimi Michael, Cui Baolong, Xu Xingbo, Kalucka Joanna Maria, Bösch Florian, De Oliveira Tiago, Conradi Lena-Christin
| 期刊: | Molecular Therapy Oncology | 影响因子: | 5.300 |
| 时间: | 2024 | 起止号: | 2024 Jun 9; 32(3):200828 |
| doi: | 10.1016/j.omton.2024.200828 | 研究方向: | 肿瘤 |
| 疾病类型: | 肠癌 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
